Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II IMRT plus nivolumab in locally advanced NSCLC (stage III, non-surgical, non-chemo candidates)
2020-000958-98Phase 2Terminated
- Sponsor
- Centre Eugène Marquis
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in non-small cell lung cancer (NSCLC), sponsored by Centre Eugène Marquis. Primary endpoint: Disease control. Started Aug 2020; status: terminated.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2020-000958-98.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000958-98.